Close Menu
  • News
  • Stocks
  • Bonds
  • Commodities
  • Collectables
    • Art
    • Classic Cars
    • Whiskey
    • Wine
  • Trading
  • Alternative Investment
  • Markets
  • More
    • Economy
    • Money
    • Business
    • Personal Finance
    • Investing
    • Financial Planning
    • ETFs
    • Equities
    • Funds

Subscribe to Updates

Get the latest markets and assets news and updates directly to your inbox.

Trending Now

MSK Ghent Declines to Return Nazi-Looted Painting, Citing Past Compensation

November 25, 2025

Vanity Fair‘s Soon-To-Be-Published Hollywood Issue Includes an Intimate, Abstract Portrait of Olivia Nuzzi

November 25, 2025

Gold Pocket Watch Recovered From the Titanic Sets New Auction Record at $2.3 M.

November 25, 2025
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
The Asset ObserverThe Asset Observer
Newsletter
LIVE MARKET DATA
  • News
  • Stocks
  • Bonds
  • Commodities
  • Collectables
    • Art
    • Classic Cars
    • Whiskey
    • Wine
  • Trading
  • Alternative Investment
  • Markets
  • More
    • Economy
    • Money
    • Business
    • Personal Finance
    • Investing
    • Financial Planning
    • ETFs
    • Equities
    • Funds
The Asset ObserverThe Asset Observer
Home»Business
Business

Weight-loss drug coverage rises among largest US employers, Mercer survey finds By Reuters

News RoomBy News RoomNovember 20, 2024
Share
Facebook Twitter LinkedIn Pinterest Email

By Amina Niasse

NEW YORK (Reuters) – About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer (NASDAQ:) released on Wednesday.

Mercer also said 64% of U.S. employers with over 20,000 employees covered weight-loss drugs in 2024, compared with 56% last year.

That includes the highly effective newer GLP-1 drugs Wegovy from Novo Nordisk (NYSE:) and Eli Lilly (NYSE:)’s Zepbound that have been shown in trials to reduce weight by 15% to 20%, as well as older drugs in the class that promote less weight loss, such as Novo’s Saxenda.

Obesity drugs have driven costs up for employers this year and contributed to an increase in overall healthcare benefit costs, the survey found, resulting in changes to how patients access the drugs.

“Cost is clearly a concern, and employers are adding authorization requirements to ensure the medications are used by members who will benefit the most,” said Tracy Watts, Mercer’s national leader for U.S. health policy.

Those include clinical coordination, or management of patient care by pharmacy benefit managers and insurers, the report said.

Only about 24.4 million Americans have access to GLP-1 drugs through commercial health plans, Reuters reported on Monday. Mercer’s survey question referred to weight-loss drugs from any class of medicines.

Companies with over 500 employees also increased fertility treatment coverage, with 47% paying for in vitro fertilization, in which an egg is fertilized outside of the uterus, up from 45% in 2023.

For all employer health plans, the annual cost for a single employee rose 5% from 2023 to $16,501.

A Mercer report released in September found that employers had expected a 5.8% increase in health insurance costs, even after implementing cost-reduction measures.

To try to lower costs, employers have expanded health plan options and focused on those that have metrics comparing patient outcomes against costs, the report said.

About 65% of large employers offered three or more health plan choices in 2024. Employers with over 20,000 employees offered an average of five medical plans, Mercer said.

Nearly one-third of large employers offered an Exclusive Provider Organization health plan that limits patients to providers within its network. One-third of those plans do not require a deductible.

About 87% of Americans were enrolled in a health plan with a deductible in 2024, according to a KFF survey.

Mercer’s survey covers 2,194 U.S. employers ranging from those with 50 to over 20,000 employees.

(This story has been corrected to remove reference to self-insured plans, to clarify on the plan as an Exclusive Provider Organization health plan, and to show that the survey included employers of 50 people or more, in paragraphs 9, 13 and 15 respectively)

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Bank of Israel quashes rate cut rumors

Should You Invest in Woodward (WWD)?

What to watch for at China’s Communist Party’s plenum

Jamie Dimon issues private credit warning: ‘When you see one cockroach, there are probably more’

European hostility could jeopardize Metro

Exclusive-Japan’s Rakuten weighing US IPO of credit card business, sources say

Dipan Mehta bullish on LG Electronics as GST cut boosts outlook

Kamala Harris doesn’t believe her presidential run was her finale: A glass ‘cliff suggests finality, and I’m not into that’

LevelBlue acquires cybersecurity co Cybereason

Recent Posts
  • MSK Ghent Declines to Return Nazi-Looted Painting, Citing Past Compensation
  • Vanity Fair‘s Soon-To-Be-Published Hollywood Issue Includes an Intimate, Abstract Portrait of Olivia Nuzzi
  • Gold Pocket Watch Recovered From the Titanic Sets New Auction Record at $2.3 M.
  • Alphabet’s stock rises as possible Meta chip deal highlights new twist in the AI trade
  • Harmony Greenlights US$1.75 Billion Eva Copper Mine Bildout

Subscribe to Newsletter

Get the latest markets and assets news and updates directly to your inbox.

Editors Picks

Vanity Fair‘s Soon-To-Be-Published Hollywood Issue Includes an Intimate, Abstract Portrait of Olivia Nuzzi

November 25, 2025

Gold Pocket Watch Recovered From the Titanic Sets New Auction Record at $2.3 M.

November 25, 2025

Alphabet’s stock rises as possible Meta chip deal highlights new twist in the AI trade

November 25, 2025

Harmony Greenlights US$1.75 Billion Eva Copper Mine Bildout

November 25, 2025

GoFundMe Created Donation Pages for Hundreds of Museums. The Only Problem: They Didn’t Tell the Museums.

November 25, 2025
Facebook X (Twitter) Instagram
© 2025 The Asset Observer. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Press Release
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.